Number Т. 10, № 3-4 (39-40)

World Conference on Lung Cancer 2020: new in the treatment of advanced/metastatic NSCLC

Summary. In early 2021, Singapore hosted the World Conference on Lung Cancer 2020, which addressed, among other things, the treatment of advanced / metastatic non-small cell lung cancer (NSCLC). Lung cancer is one of the most common causes of death from cancer worldwide. Platinum-based chemotherapy has historically been the standard first-line treatment for patients with advanced NSCLC, especially those without the EGFR and ALK3-5 mutations. However, the development of oncology and the emergence of immunotherapeutic drugs targeting programmed cell death-1 (PD-1) receptors have significantly expanded the therapeutic options for treating patients with advanced/metastatic NSCLC. It has been shown that this approach can significantly improve clinical outcomes of treatment compared to standard chemotherapy regimens [1]. Currently, oncologists have three main therapeutic strategies to choose from when treating patients with advanced / metastatic NSCLC without susceptible mutations: immunotherapy alone, immunotherapy + immunotherapy combinations, or immunotherapy + chemotherapy combinations. How do you make this choice? In this context, the results of two studies of the efficacy of pembrolizumab — KEYNOTE-189 and KEYNOTE-042, are interesting, the results of which were presented during the World Conference on Lung Cancer 2020.

No Comments » Add your
Leave a comment